Lynda Charters

The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.

Recent research highlights inferred sensitivity mapping as a promising method to assess retinal function in geographic atrophy, enhancing clinical trial outcomes.

A study reveals that ophthalmic artery angioplasty improves vision and functionality in patients with late-stage age-related macular degeneration.

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration.

AMD treatment may become unrecogniable as gene therapies evolve.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Long-term cannabis use may reduce the risk of proliferative vitreoretinopathy after retinal detachment surgery, suggesting potential therapeutic benefits.

A study reveals significant treatment burdens for patients with AMD and DME, highlighting the need for improved education and support to enhance outcomes.

A rare case of tubulointerstitial nephritis and uveitis syndrome in a teenager highlights the importance of multidisciplinary diagnosis and management.

Enhanced screenings and a unified registry could save vision and lives.

Researchers reveal that retinal microvasculature analysis via OCTA may enhance noninvasive cardiovascular risk assessment, potentially improving coronary artery stenosis detection.

Re-Vana Therapeutics and Boehringer Ingelheim forge a $1 billion partnership to develop innovative extended-release therapies for eye diseases, enhancing patient care.

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

Mucormycosis emerges as a critical concern in diabetic patients with sudden vision loss, highlighting the need for prompt diagnosis and treatment.

A recent study reveals cannabis use may lower the risk of proliferative vitreoretinopathy after retinal detachment repair, suggesting potential therapeutic benefits.

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants in the MERTK gene.

Patients are highly motivated to slow disease progression with GA drugs and healthy lifestyle.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

A new study from China revealed a genetic link between coffee consumption and age-related macular degeneration (AMD).

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

Investigators take an in-depth look at all aspects of the technology.

Brazilian regulatory authority ANVISA grants marketing authorization for Ranivisio.

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs.

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings suggest that neurologic diseases impact ocular health.

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.